A. The pilot observational study concluded that intravenous opioid patient-controlled therapy is a feasible and acceptable way to relieve refractory breathlessness in palliative-care patients, supporting this new therapeutic concept for opioid administration [Schmitz et al., 2016, PMID 26578404].